Capstone Therapeutics Corp. (OTCPK:CAPS) entered into an agreement to acquire an unknown stake in Instone Co (TOTALSTONE) on March 2020. The existing holders of TOTALSTONE’s membership interests (other than its mezzanine lender) will receive preferred units valued at $20.5 million, with a quarterly dividend, that if not paid, is added to the preferred units’ value, at a rate of between 7% and 20% based on TOTALSTONE’s financial performance. The preferred units are redeemable July 1, 2023, 39 months from issuance. Capstone will initially own 100% of TOTALSTONE’s outstanding common units and receive certain funding from TOTALSTONE, in exchange for corporate governance and other management expertise. The company’s primary business activity going forward will be the operations of TOTALSTONE. The agreement stake will be effective in April 1, 2020.